Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

NCT02183467 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 1356, low dose
DRUG: BI 1356, high dose
DRUG: Placebo
DRUG: Moxifloxacin

Sponsor

Boehringer Ingelheim